Author:
Lenk Christine,Unterthurner Sabine,Schuster Maria,Weiller Markus,Antoine Gerhard,Malisauskas Mantas,Scheiflinger Friedrich,Schwarz Hans-Peter,de la Rosa Maurus,Reipert Birgit M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference48 articles.
1. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol. 2004;127:379–91.
2. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost. 1992;67:600–2.
3. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109:546–51.
4. Dickneite G, Zollner S, Weimer T, Schürmann D, Schmidbauer S, Raquet E, et al. Prolonged serum half-life of a recombinant fusion protein linking activated coagulation factor VII with albumin (FVIIA-FP) in different preclinical species. J Thromb Haemost. 2011;9(Supplement 2):385.
5. Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the rFVIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012;10:773–80.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献